8-Hydroxyquinoline platinum(ii) loaded nanostructured lipid carriers: synthesis, physicochemical characterization and evaluation of antitumor activity by Boztepe, Tugce et al.
rsc.li/njc
NJC




Chechia Hu, Tzu-Jen Lin et al. 
Yellowish and blue luminescent graphene oxide quantum dots 
prepared via a microwave-assisted hydrothermal route using 






New Journal of Chemistry  A journal for new directions in chemistry
This is an Accepted Manuscript, which has been through the  
Royal Society of Chemistry peer review process and has been 
accepted for publication.
Accepted Manuscripts are published online shortly after acceptance, 
before technical editing, formatting and proof reading. Using this free 
service, authors can make their results available to the community, in 
citable form, before we publish the edited article. We will replace this 
Accepted Manuscript with the edited and formatted Advance Article as 
soon as it is available.
You can find more information about Accepted Manuscripts in the 
Information for Authors.
Please note that technical editing may introduce minor changes to the 
text and/or graphics, which may alter content. The journal’s standard 
Terms & Conditions and the Ethical guidelines still apply. In no event 
shall the Royal Society of Chemistry be held responsible for any errors 
or omissions in this Accepted Manuscript or any consequences arising 




This article can be cited before page numbers have been issued, to do this please use:  T. Boztepe, S.






Please do not adjust margins 
Please do not adjust margins 
Received 00th January 20xx, 
Accepted 00th January 20xx 
DOI: 10.1039/x0xx00000x 
 
8-Hydroxyquinoline platinum(II) Loaded Nanostructured Lipid 
Carriers: Synthesis, Physicochemical Characterization and 
Evaluation of Antitumor Activity  
Boztepe T. a, Scioli-Montoto S. b, Ruiz M.E. b, Alvarez V.A. c, Castro G.R. a, León I.E. d * 
The incidence of cancer and the death rate increases every year in the world. The drug 8-hydroxyquinoline platinum(II) 
[PtCl(8-O-quinoline)(dmso)] (8HQ-Pt) has been identified as a promising antitumor complex. Nanostructured lipid carriers 
(NLC) are the second-generation drug nanocarrier systems that present superior advantages over other kinds of colloidal 
carrier systems. 8HQ-Pt compound loaded NLC formulations of cetyl esters (SS) were synthesized by ultrasonication in 
presence of two different liquid oils; capric triglyceride, or olive oil. The physicochemical and microscopic characterizations 
of NLC were analyzed by dynamic light scattering (DLS), transmission electron microscopy (TEM), fourier transformed 
infrared spectroscopy (FTIR), thermogravimetric analysis (TGA), differential scanning calorimetry (DSC) and X-ray diffraction 
analysis (XRD). In vitro drug release and cytotoxicity, cell uptake and apoptosis assays against the human colon cancer HT -
29 were investigated. The results showed that NLCs indicated a narrow size distribution in the range of 136-159 nm mean 
particle diameter. The thermal characteristics analysis confirmed the stability of NLCs up to 185 °C. Encapsulation efficiencies 
of the 8HQ-Pt compound in NLCs were about 80% and 8HQ-Pt compound in the formulations showed controlled release 
profile during 72 h. The release profile of these two different formulations and the antitumor effect on HT-29 cell line were 
compared with the free 8HQ-Pt compound. The cellular uptake of two different NLC groups was proved by fluorescence 
microscopy and the presence of capric triglyceride liquid oil in the formulation increased the capacity of drug delivery to 
intracellularly when compared with olive oil.
Introduction 
Cancer is the main cause of death worldwide, grew to 18.1 million 
novel cases and 9,6 million deaths in 2018. Lung, breast, colorectal, 
prostate and stomach cancers are leading types of cancer globally. 
Colorectal cancer (CRC) is the third of the most common cancers 
worldwide with approximately 1.8 million people diagnosed in 2018 
and is ranked as the second leading cause of death (880.000 deaths 
in 2018) after lung cancer 1. Genetic and lifestyle factors such as 
unhealthy nutrition, obesity, smoking, alcohol and lack of physical 
activity raise the risk of CRC 2.  
Platinum-based metallodrugs have been used in the treatment of 
various solid tumors for decades, although they show a high level of 
toxicity and low bioavailability 3. Cisplatin, carboplatin and oxaliplatin 
are well-known platinum(II) compounds that are anticancer drugs 
approved by the Food and Drug Administration (FDA, USA) for 
chemotherapy in the clinic 4. Cisplatin is also called as cis-
diamminedichloroplatinum(II) was used for bladder, testicular, 
ovarian, cervical, head, neck, colorectal and lung cancers 5,6. Due to 
an active species of cisplatin, the drug is able to interact with purine 
nucleotide bases of DNA and induces DNA distortion, leading to 
cancer cell apoptosis 7. Although carboplatin and oxaliplatin have a 
similar mechanism of action as cisplatin and exhibit some advantages 
over cisplatin, the drawback of dose-limiting toxicities and intrinsic 
or acquired resistance remain 8. In order to reduce the side effects 
and overcome the resistance of cisplatin, it has been investigated on 
new platinum drugs with elevated antitumor efficiency and more 
tolerable toxicological profile 9. 
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Figure 1: Chemical structure of [PtCl(8-O-quinoline)(dmso)] ( 8HQ-Pt) compound 
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Clioquinol has been used for medical applications such as the 
treatment of Alzheimer’s disease because it is able to interact with 
metals like zinc or copper 10. Clioquinol interaction of metals with 
DNA causes high cytotoxicity and induces apoptosis of cancer cells 11. 
The drug 8-hydroxyquinoline platinum(II) [PtCl(8-O-
quinoline)(dmso)] (8HQ-Pt) (Figure 1) was derived from clioquinol 
and showed antitumor activity without generating resistance and 
side effects up today when it is compared with cisplatin 12. 
Nanosystems were developed to reduce and eliminate some 
disadvantages of many drugs with administration problems like 
cancer drugs, for instance, dosage-related side effects, drug 
resistance and poor aqueous solubility. These systems may provide 
improved drug performance by controlled release, i.e. preventing 
sudden increases in blood levels and leading to a decrease in the side 
effects of the active substance 13. Furthermore, the use of non-toxic 
lipids without organic solvents in the synthesis ensures 
biocompatible, biodegradable and non-irritating nanoparticles 14,15.  
Among nanosystems, nanostructured lipid carriers (NLC) are one of 
the most promising carriers for drug delivery. NLCs are second-
generation solid lipid nanoparticles that consist of a mix of solid and 
liquid lipids stabilized with a biocompatible active compound 16. NLCs 
were developed to overcome some drawbacks of solid lipid 
nanoparticles (SLN), such as drug instability and low drug loading 
capacity 17. NLCs have a high capacity to load drugs and increase the 
solubility of drugs, especially hydrophobic molecules 18.  
The current study aims to improve the availability of the [PtCl(8-O-
quinoline)(dmso)] under physiological environments by an efficient 
encapsulation in presence of two different types of liquid oils: capric 
triglyceride and olive oil, in order to achieve a sustained drug release 
profile and enhanced antitumor effects. Drug encapsulation 
efficiency, cytotoxicity, cell uptake and apoptosis analysis of 
nanoparticles were performed. Physicochemical characterization of 
the formulations was carried out by dynamic light scattering (DLS), 
transmission electron microscopy (TEM), Fourier transformed 
infrared spectroscopy (FTIR), thermogravimetric analysis (TGA), 
differential scanning calorimetry (DSC) and X-ray diffraction (XRD).  
 
Results and discussion 
Formulation development and nanoparticle morphology  
All the formulations were produced with the same type and amount 
of solid lipid and surfactant, changing only the liquid oil (NLCA: capric 
triglyceride, NLCB: olive oil). For both 8HQ-Pt compound loaded 
formulations, the initial amount of drug was constant, and the 
encapsulation efficiency were 82.1 ± 0.9 and 81.5 ± 3.72 for (8HQ-
Pt)-NLCA (8HQ-Pt)-NLCB, respectively. 
The morphological structure and size distribution of nanoparticles 
were analyzed by TEM (Figure 2). Both NLC systems exhibited 
spherical morphology and the size of both formulations are smaller 
than 200 nm. TEM images revealed the size of NLCA was smaller than 
NLCB. These results were confirmed by DLS analysis.  
The mean particle size and polydispersity index (PdI) of the 
formulations were determined by DLS. The average (± sd) particle 
size of NLCA, (8HQ-Pt)-NLCA, NLCB and (8HQ-Pt)-NLCB were 136.0 ± 
1.1, 136.3 ± 0.5, 159.0 ± 2.0 and 144.0 ± 2.0 nm respectively (Table  
Table 1: Average size and PdI of NLCs by DLS. No significant differences were found among 
formulations (ANOVA, p>0.05). Zav - Average size (nm), PdI – Polydispersity index. 
 
1). The PdI values for all the formulations were determined around 
0.2 which indicates monodisperse particle sizes 19.  
 
Physicochemical characterization by FTIR, TGA, DSC and XRD 
analysis 
FTIR analysis was performed to identify the surface functional groups 
and their interaction with the matrix. Cetyl esters (SS) showed 
characteristic peaks in the range of 2915 cm-1 and 2847 cm-1 (alkane 
C-H stretching) and 1731 cm-1 (aldehyde C=O stretching). These 
peaks were observed in the spectra of NLCA, (8HQ-Pt)-NLC-A, NLCB 
and (8HQ-Pt)-NLCB nanoparticles (Figure 3) 20. 
The FTIR spectra of surfactant Poloxamer 188 showed characteristic 
peaks of the alkane group (C-H peak at 2873 cm-1), the alcohol group 
(O-H stretching peak at 1340 cm-1) and the secondary alcohol group 
(C-O stretching peak at 1096 cm-1) 21. 
The liquid oil capric triglyceride that was incorporated in the 
formulations NLCA and (8HQ-Pt)-NLCA showed absorption bands at 
2923 cm-1, 1739 cm-1 and 1148 cm-1 which are related with alkane C-
H stretching, aldehyde C=O stretching and aliphatic ether C-O 
stretching, respectively. Olive oil contained in the formulations NLCB 
and (8HQ-Pt)-NLCB exhibited some peaks at 2923 cm-1 (alkane C-H 
stretching), 1741 cm-1 (esters C=O stretching) and 1160 cm-1 (tertiary 
alcohol C-O stretching) 22,23. 
TGA and DSC analysis were used to analyze the thermal 
characteristics of the nanoparticles. According to the TGA results, 
NLCA, (8HQ-Pt)-NLCA, NLCB and (8HQ-Pt)-NLCB exhibited a biphasic 
thermal behavior. The first thermal degradations appeared in the 
range of 186-338 ºC with a weight loss of 37.3%, 33.9%, 33.2% and 
Formulations Zav (nm) PdI 
NLCA 136.0 ± 1.1 0.218 ± 0.016  
NLCB 159.0 ± 2.0 0.226 ± 0.010  
(8HQ-Pt)-NLCA 136.3 ± 0.5 0.218 ± 0.050  
(8HQ-Pt)-NLCB 144.0 ± 2.0 0.210 ± 0.013  
Figure 2: TEM images of NLCs; 8HQ-Pt compound loaded (left), empty (right). 
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30.3%, respectively and are related to the cetyl esters (SS). All the 
formulations preserved their consistencies up to 185 ºC. That allows 
the NLCs to endure in release media. The second thermal 
degradations appeared in the range of 338 – 421 ºC with a weight 
loss of 62.5%, 65.9%, 66.0% and 68.7% respectively. TGA graph 
showed that NLCB formulations were more stable than NLCA 
formulations (Figure SM1). This fact can be attributed to the 
presence of high content of unsaturated fatty acids (i.e. about 85%) 
in olive oil in the NLCB formulation allowed to interact better with the 
drug 23.  
DSC curves of the free 8HQ-Pt compound, NLCA, (8HQ-Pt)-NLCA, 
NLCB, (8HQ-Pt)-NLCB, cetyl esters (SS) and Poloxamer 188 were 
shown in Figure SM2. All formulations displayed two endothermic 
peaks. The first peaks were observed in the range of 44 – 48 ºC and 
it can be attributed to the melting point temperature of solid lipid 
cetyl esters (SS) which is approximately 44 ºC 15. The second peaks 
were observed in the range of 46 – 52 ºC that could be associated 
with the melting point temperature of Poloxamer 188 
(approximately 53 ºC). The free 8HQ-Pt compound did not show 
degradation up to 100 ºC which indicates its good stability under the 
operational conditions. 
Crystalline structures of the NLCs with or without 8HQ-Pt compound 
(NLCA, (8HQ-Pt)-NLCA, NLCB and (8HQ-Pt)-NLCB were analyzed by XRD 
to identify the polymorphism of the lipid matrix. Fats can crystalize 
in α (unstable), β’ (metastable) and β (stable) polymorphic forms 24. 
The assignment of XRD peaks indicates a mixture of β and β’ forms 
of the lipids. All the NLC formulations showed comparable patterns. 
The patterns equivalent to NLC formulations displayed peaks 
correlative to cetyl esters SS (19.10°, 21.32° and 23.25°) and confirm 
the solid crystalline structure of NLCs (Figure 4) 15. Short spacing (d) 
of crystal lattices is utilized to characterize the polymorphic forms. 
NLC formulations exhibited short spacing at 0.46 nm (β form), 0.42 
nm (β’ from) and 0.38 nm (β or β’ form) where the peaks were 
observed at 19.10°, 21.32° and 23.25°, respectively 25. Polymorphic 
behavior due to the crystalline structure of lipid nanoparticles is 
crucial for stability during storage and the release properties of the 
loaded drug from the nanoparticles. β or β’ forms display higher-
order packing and highest thermodynamic stability. Thus, 
undesirable drug expulsions could be prevented 20,26. 
 
In vitro drug release assay 
In vitro drug release assay was performed at pH 4.4 in 200 mM 
acetate buffer by the dialysis method. 2.0 mL of each formulation as 
well as a free-drug suspension were placed into dialysis bags and the 
release profiles were analyzed (Figure 5). Free 8HQ-Pt reached 100% 
release in the first 3 h. In comparison with free 8HQ-Pt compound 
suspension, both formulations displayed slow drug release rate, with 
approximately 75% (8HQ-Pt)-NLCA and 90% (8HQ-Pt)-NLCB released 
in 72 h. Figure 5 showed hyperbolic curves for 8HQ-Pt compound 
release kinetic from the nanoparticles. When studying the drug 
release from the nanoparticles, it was found that the date better 
Figure 3: FTIR spectra of Cetyl esters (SS), Poloxamer 188, liquid oils; capric triglyceride 
and olive oil and NLCA, (8HQ-Pt)-NLCA, NLCB and (8HQ-Pt)-NLCB nanoparticles. 




































































































































ARTICLE Journal Name 
4  |  J. Name. , 2012, 00,  1-3  This journal is © The Royal Society of Chemistry 20xx 
Please do not adjust margins 
Please do not adjust margins 
adjust to a first-order release kinetic 27. (Eq. 1), according to all the 
statistical goodness of fit measures considers (R2, R2-adj, AIC, MSE 
and residual structure). 
 
  𝑭𝒕 =
𝑴𝒕
𝑴∞
× 𝟏𝟎𝟎 = 𝑭𝒎𝒂𝒙(𝟏− 𝒆
−𝒌∙𝒕)   Eq. 1 
 
In the equation, Ft is the percentage released at time t, Mt and M∞ 
are the cumulative amounts of the compound released at time t and 
infinite time, respectively; Fmax and k are the parameters to be 
estimated, also known as the scale and shape parameters, 
respectively. The results of the modelling analysis are shown in Table 
SM1, along with some goodness of fit measures. 
A first-order kinetic means that the device releases the drug in a way 
that is proportional to the amount of drug remaining in its interior. 
Despite that is difficult to conceptualize this model in a theoretical 
basis 28, it is informative to compare the value of the kinetic constant 
k (scale parameter) among the formulations since it contains the 
information about the influence of the formulation on the drug 
release. As it can be seen in Table SM1, while the free 8HQ-Pt 
compound on the dialysis bag shows a k=0.7, the nanoparticles 
possess values of 0.23 and 0.12 (for NLCA and NLCB, respectively). In 
other words, the nanoparticles were able to control the release 
speed by decreasing the kinetic constant more than a half, in 
comparison with the free 8HQ-Pt compound. 
 
Cytotoxicity assay 
The human intestinal cell line HT-29 was isolated from colon 
adenocarcinoma cells 29. 95% of colorectal tumors are 
adenocarcinoma which becomes malignant from epithelial cells of 
the colorectal mucosa and related with the glands 30. HT-29 cell line 
is one of the most used in vitro models in the anticancer studies. It is 
reported that HT-29 cell line showed resistance to chemotherapy 
drugs 31,32. model to clarify the mechanism of acquired resistance in 
preclinic cancer investigations 33.  
Cell cytotoxicity assay was performed for NLCs and free 8HQ-Pt 
compound on HT-29 colon carcinoma cell line by MTT analysis (Figure 
6). Cells were treated with 5, 10 and 25 μM concentration of 8HQ-Pt 
compound for 24 h. The results showed that unloaded NLCs were 
non-toxic while (8HQ-Pt)-NLCA and (8HQ-Pt)-NLCB showed a 
cytotoxic effect in HT-29 cells correlated with drug concentration. 
The cell viability values dropped to 45.0% (free drug), 44.4% ((8HQ-
Pt)-NLCA), 78.5% ((8HQ-Pt)-NLCB) for 5 μM, 12.0%, 17.9%, 54.4% for 
10 μM and 11.0%, 10.1%, 16.5% for 25 μM, respectively. Moreover, 
the type of liquid oil has a different effect on cell viability. (8HQ-Pt)-
NLCA synthesized with capric triglyceride exhibited more cytotoxicity 
than (8HQ-Pt)-NLCB synthesized with olive oil but showed similar 
cytotoxic effect with the free 8HQ-Pt compound. This result can be 
attributed to 8HQ-Pt compound was released in a time-dependent 
controlled manner from the nanoparticle in 24 h. On Figure 5 is 
displayed that the release of 8HQ-Pt from NLCA and NLCb roughly is 
75% compared to 100% of free drug so which means that 8HQ-Pt-
NLCA is possess approximately 25% more cytotoxic effect than the 
free drug. This advantage could be significant considering a potential 
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iv administration in where the injected formulation is circulating in 
the blood flow to reduce undesirable secondary effects. 
 
Figure 6: Cell cytotoxicity 8HQ-Pt loaded NLC formulations in HT-29 cell line. 
Concentration-dependent cytotoxicity of free 8HQ-Pt compound and 8HQ-Pt loaded 
NLCs in HT-29 cells for 24 h. 
Cellular uptake of NLCs 
Cellular uptake of NLCs into HT-29 cells was performed to evaluate 
the internalization of the nanoparticles. Firstly, the NLCs were 
labelled with fluorescent probe DiOC18 and then, the cells were 
incubated with the empty labelled nanoparticles using three 
different concentrations of NLCs (equivalent amount for 5, 10 and 25 
μM (8HQ-Pt)-NLCs for 6 h. Subsequently, the fluorescent signals 
were followed by flow cytometry. It was observed that the cellular 
uptake of NLCs increased directly correlated with their 
concentrations. Furthermore, the results showed that NLCA was 
more capable to penetrate to the HT-29 cells than NLCB (Table 2). 
This data confirmed the cytotoxicity assay result. Neves et al. 
compared cellular uptake properties of NLC and SLN and emphasized 
that NLCs exhibited higher internalization to the colon carcinoma 
cells due to the presence of liquid oil 34. 
 
Table 2: Cell uptake of DiOC18-loaded cetyl esters (SS) NLCs in HT-29. Flow cytometry 
was utilized to detect the cell uptake of labelled NLCs. The cells were incubated for 6 h 
at the concentrations that equivalent amount for 5, 10 and 25 μM Pt-NLCs. 
Concentration (μM) NLCA NLCB 
5 54.7 22.5 
10 72.1 30.7 
25 88.1 55.0 
 
In addition to the presence of liquid oil, our study also revealed the 
importance of the type of liquid oil. The NLCs with capric triglyceride 
achieved more cellular uptake efficiency than the NLCs with olive oil. 
Safwat et al. analyzed the effect of 3 types of liquid oils (Labrafil®, 
Labrasol® and Labrafac lipophile®) to the antitumor activity of NLC. 
Simvastatin loaded NLCs with Labrasol® showed the highest cellular 
uptake and cytotoxic effect on MCF-7 cancer cells 35. Lan et al. 
reported that lipid-coated cisplatin showed enhanced cellular uptake 
in CAL 27, SCC 15 and FaDu cancer cell lines when compared with 
free cisplatin 36.  
 
Apoptosis 
Antitumor drugs have effectiveness to prevent cell proliferation and 
generate cell apoptosis. During apoptosis process, 
phosphatidylserine residues translocate to the outer of the cell 
membrane. Annexin V–FITC is a fluorescent dye that binds to 
phosphatidylserine receptor. Thus, the apoptotic cells become 
detectable by fluorescence assays 37. 
HT-29 cells were stained with Annexin V–FITC/PI apoptosis detection 
kit after 48 h treatment. Antitumor activity of the free 8HQ-Pt 
compound and (8HQ-Pt)-NLCA were confirmed by flow cytometry. 
Figure 7 shows the percentage of vital (V-/PI-), the early apoptotic 
(V+/PI-), the late apoptotic (V+/PI+) and the necrotic (V-/PI+) 
subpopulations in the dot plot. The results demonstrated that free 
8HQ-Pt compound and (8HQ-Pt)-NLCA induced 13.0% and 12.6% for 
1.0 μM, 53.8% and 33.3% for 2.5 μM, 71.4% and 70.3% of cells in late 
apoptosis (V+/PI+), respectively. These results confirmed the cell 
viability assays that the late apoptotic cells values increased in a 
concentration-dependent manner in cells treated with free 8HQ-Pt 
compound and (8HQ-Pt)-NLCA. On the other hand, empty 
nanoparticles exhibited very low apoptosis level. Ruiz et al. reported 
the antiproliferative effect of 8HQ-Pt by measuring mitochondrial 
transmembrane potential. They also proved that its apoptotic effect 
is in a concentration-depended manner in the MG-63 cell line 12. 
Platinum-based drugs show limited plasma stability and low delivery, 
although their apoptotic effects 38. Drug stability is increased by 
nanoencapsulation due to the interaction of the drug with the lipid 
18. Cacicedo et al. demonstrated that the antitumor activity of 
Metvan was enhanced by NLC encapsulation. This result was 
attributed to the drug protection property of NLC and therefore, 
higher drug accumulation occurred in the tumor cells and caused 
more apoptosis 39. Thus, NLCs are encouraging nanosystems to 





Cetyl esters (SS) and capric triglyceride lipids were kindly donated by 
Croda (Argentina). Poloxamer 188 and 3,3’-
dioctadecyloxacarbocyanine perchlorate (DiOC18) were purchased 
from Sigma–Aldrich (Buenos Aires, Argentina). DMEM (Dulbecco’s 
Modified Eagles Medium) and TrypLE™ were purchased from Gibco 
(Gaithersburg, MD, USA), and FBS (fetal bovine serum) was bought 
from Internegocios S.A. (Argentina). Annexin V, Fluorescein 
isothiocyanate (FITC)/PI and tetrazolium salt MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium-bromide) from 
Invitrogen Co. (Buenos Aires, Argentina). Other reagents were of 
analytical grade from available commercial sources and used as 
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Preparation of 8HQ-Pt compound 
The [PtCl(8-O-quinoline)(dmso)] was synthesized and characterized 
according to Martín Santos C, et al. 11. The product was obtained 
following the general procedure as a yellow-orange solid (78% yield) 
without further purification.  
1H NMR (300 MHz, CD2Cl2) δ 9.41 (dd, J = 10.7, 1.2 Hz, 1H), 
8.38 (dd, J = 8.4, 1.1 Hz, 1H), 7.58-7.40 (m, 2H), 7.02-7.06 (m, 2H), 
3.61 (s, 6H). 13C NMR (75 MHz, CD2Cl2) δ 148.6, 148.3, 140.3, 140.2, 
131.5, 131.0, 121.7, 115.6, 114.6. 46.6. 195Pt NMR (64.5 MHz, 
CD2Cl2) δ: -2760.7. HRMS (FAB+): calcd for C11H12ClNO2PtS (M+): 
452.9915; found: 452.9928. Anal. calcd. for C11H12ClNO2PtS: 
C, 29.18; H, 2.67; N, 3.09; found: C, 29.00; H, 2.67; N, 2.94. 
 
Figure 7: Apoptotic effects of free 8HQ-Pt compound and (8HQ-Pt)-NLCA at 1.0 μM, 2.5 μM and 5.0 μM after 48 h incubation with HT-29 cells. 
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Preparation of 8HQ-Pt compound loaded NLCs 
[PtCl(8-O-quinoline)(dmso)] compound loaded NLCs were prepared 
by ultrasonication technique 20,40. Briefly, 400 mg of solid lipid cetyl 
esters (SS) (2.0%, w/v) was melted in a water bath at 70 °C and mixed 
with 2.0 mg of the 8HQ-Pt compound. [PtCl(8-O-quinoline)(dmso)] 
was dissolved in 200 μL capric triglyceride or olive oil (1.0%, v/v). 
After 15 min, 20 mL of the hot aqueous solution of Poloxamer 188 
(4.5%, w/v) was added to the lipid phase. Instantly, the mixture was 
ultrasonicated at 65% amplitude for 30 min equipped with 6 mm 
titanium tip (ultrasonic processor Cole Parmer, USA, 130 Watts). 
After sonication, the formulation was cooled down at room 
temperature and stored at 4 °C. Two different groups of lipid 
formulations were synthesized. The first group contained capric 
triglyceride: (8HQ-Pt)-NLCA and its control NLCA without the drug. 
The second one was similarly prepared and contained olive oil (74% 
oleic acid, 13% palmitic acid and small amount other fatty acids): 
(8HQ-Pt)-NLCB and its control NLCB. 
 
Measurement of encapsulation efficiency 
Encapsulation efficiency (EE, %) was calculated by measuring the 
concentration of the free drug in solution. Briefly, 500 μL of final 
suspension was transferred to an ultrafiltration centrifugal device 
(MWCO 10.000, Microcon®, Millipore, MA, USA) and centrifuged at 
12000 ×g for 30 min. After centrifugation, the supernatant containing 
the free drug was measured by HPLC. The EEs (%) of the NLCs were 
estimated following equation 2 (Eq. 2): 
 
              EE (%) = (wi – wfd) ∕ wi × 100             Eq. 2       
where wi is the initial amount of Pt compound added to the 
formulation and wfd is the amount of free Pt compound after the 
ultrafiltration process. 
 
HPLC analysis of Pt compound 
Chromatographic analysis was performed using HPLC (Gilson SAS, 
Villiers-Le-Bel, France) with UV detection. Chromatographic 
separation was performed in a Lichrosphere® 100 RP-18 (250 mm x 
4.6 mm, 5 μm, Merck KGaA, Darmstadt, Germany) column. The 
mobile phase was methanol and 0.1% phosphoric acid solution 
(60:40). The system was operated isocratically at 1.0 ml/min flow 
rate and the detection was performed at 262 nm. Samples were 
diluted with mobile phase and centrifuged (15.000 xg for 5 min at 4 
°C) prior to their injection (20 μL). 
The method was validated in terms of linearity, precision, and 
specificity, over the range of expected concentrations (0.1 – 200 μM). 
Linear regression for the Pt compound (p< 0.0001) was observed in 
the concentration range of 0.2 – 110 μM, with a coefficient of 
determination R2 = 0.997. The 95% confidence interval of the 
intercept was [-1.2322 – 0.6447]. The precision of the method was 
established at three concentration levels: 0.2, 44 and 110 μM, and in 
all cases RSD values were below 3%. The method was specific for 
8HQ-Pt compound and no interfering peaks were observed. 
 
Particle size and polydispersity index (PdI)  
The average diameter and size distribution of lipid nanoparticles 
were measured by dynamic light scattering (DLS) (Nano ZS Zetasizer, 
Malvern Instruments Corp, UK) at 25 °C in polystyrene cuvettes with 
a thickness of 10 mm. Measurements were performed in 10 mm path 
length capillary cells, using deionized water (Milli-Q®, Millipore, Ma., 
USA). The PdI value was also determined. All the measurements were 
carried out in triplicate.  
 
Transmission electron microscopy (TEM) 
TEM analysis was performed using Jeol-1200 EX II-TEM microscope 
(Jeol, MA, USA). The NLC dispersion was 1:10 diluted with ultra-pure 
Milli-Q® water, and 10 μL of the dispersion was spread onto a 
collodion-coated Cu grid (400-mesh). Liquid excess was removed 
with filter paper and for contrast enhancement a drop of 
phosphotungstic acid as added to the NLCs dispersion.  
 
Fourier transformed infrared spectroscopy (FTIR) 
Fourier transform infrared spectroscopy (FTIR) was performed by 
using a Nicolet 6700 (Thermo Scientific, Inc., Waltham, MA, USA) 
spectrometer. Attenuated total reflectance (ATR) mode was used to 
record spectra over the range 600 – 4.000 cm-1 are the solution of 2 
cm-1. 
 
Thermogravimetric analysis (TGA) 
TGA was achieved with the aim to analyze the thermal stability of 
cetyl esters (SS), free (8HQ-Pt) compound, NLCA, (8HQ-Pt)-NLCA, 
NLCB, (8HQ-Pt)-NLCB particles. TGA Q500 apparatus (TA Instruments, 
New Castle, DE, USA) was used to obtain TGA data. Samples of 2.0 - 
9.0 mg were accurately weighed in a platinum pan and 
measurements conducted from room temperature to 600 ºC at a 
heating rate of 10 ºC/min under nitrogen atmosphere to avoid the 
thermo-oxidative oxidation.  
 
Differential Scanning Calorimetry (DSC) analysis 
The thermal properties of cetyl esters (SS), free (8HQ-Pt) compound, 
NLCA, (8HQ-Pt)-NLCA, NLCB, (8HQ-Pt)-NLCB particles were determined 
by differential scanning calorimetry (DSC Q5000, TA Instruments, 
USA) under nitrogen atmosphere. Scans were run at 0 to 200°C range 
with heating rate of 10°C/min. 
 
X-ray diffraction (XRD) 
The X-ray diffraction patterns were obtained with a PANalytical 
X’Pert PRO diffractometer equipped with an X-ray source (Phillips 
PW 1830, PANalytical BV, the Netherlands) using CuKα radiation at 
40 kV and 40 mA, over a 2θ range of 5° – 60° with an acquisition time 
of 1s/s at each step of 0.02°. 
 
In vitro drug release assay 
Release assays were performed using dialysis membranes (MWCO 10 
kDa). The membrane was soaked in distilled water for overnight and 
filled with 2.0 ml of each formulation followed by immersion in 15.0 
mL of 200 mM acetate buffer (pH = 4.4) at 37 ºC, with continuous 
shaking at 200 rpm. Samples of 200 μL were withdrawn at regular 
intervals for 72 hours, and drug concentration was measured in 
HPLC. 
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Cell cytotoxicity assay 
HT-29 (human colon carcinoma cells) cell line was obtained from 
ATCC® (HTB-38™). Cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM; Gibco, Invitrogen Corporation, USA) supplemented 
with 10% FBS (Internegocios, Buenos Aires, Argentina) and 
antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin; Gibco, 
Invitrogen Corporation, USA) at 37ºC and under 5% CO2 atmosphere. 
Cell viability was examined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) 41. HT-29 cells were seeded in a 
96-well plate for 24 h to be attached to the plate surface. Then, the 
cells were treated with different concentrations of free (8HQ-Pt) 
compound, NLCA, (8HQ-Pt)-NLCA, NLCB, (8HQ-Pt)-NLCB particles in 
serum-free DMEM for 24 h. The medium was removed, and the cells 
were incubated with MTT reagent (0.5 mg/mL MTT in supplemented 
DMEM medium) for 3 h. Later, the absorbance was read at 570 nm 
in a microplate reader (multiplate reader multiskan FC, thermo 
scientific). Cell viability was indicated as the percentage (%) of the 
untreated control value (100% survival). 
 
Cellular uptake assay 
Cellular uptake was evaluated using empty nanoparticles labelled 
with the green fluorescent probe DiOC18 (λabs/λem= 484/501 nm). 
Concisely, 1.0 mg of DiOC18 was mixed with the melted lipid phase 
(at 70 °C) and protected from light. The formulation was prepared as 
previously described by the addition of aqueous phase and 
sonication at 65% potency for 30 min. As a result, the DiOC18 was 
100% encapsulated into the nanoparticles. The cellular uptake of 
fluorescent-labelled nanoparticles was evaluated by flow cytometry.  
HT-29 cells were plated in 12 well plate at the density of 20 ×104 cells 
per well. After 24 h, cells were treated with serum-free DMEM 
containing three different concentrations of empty NLCs (equivalent 
amount for 5, 10 and 25 μM (8HQ-Pt)-NLCs and incubated for 6 h. At 
the end of the treatment, cells were washed once with PBS. Then, 
cells were treated with 300 μL of trypLe and next, 600 μL of the 
serum-containing medium was added to each well. Later, cells were 
collected from each well to Eppendorf tubes and centrifuged at 2,500 
×g for 5 min. Supernatants were removed and cells were dispersed 
in 200 μL of PBS. Fluorescence was analyzed by FACSCalibur (Becton–
Dickinson, Franklin Lakes, NJ, USA) and the resulting values were 
evaluated by FlowJo 7.6 software. 
 
Apoptosis 
Cells were treated with the three different concentrations (1.0, 2.5, 
5.0 μM) and incubated for 48 h prior to analysis. For the staining, cells 
were washed with PBS and were diluted with 1X binding buffer, 
Annexin V-FITC and PI and incubated for 20 min at room temperature 
prior to analysis. Cells were collected using flow cytometry (BD 
FACSCalibur™) and the results were analyzed using FlowJo 7.6 
software. Four subpopulations were defined in the dot plot: the 
undamaged vital (Annexin V−/PI−), the vital mechanically damaged 
(Annexin V/PI+), the early apoptotic (Annexin V+/PI−), and the late 
apoptotic (Annexin V+/PI+) subpopulations. 
 
Statistical analysis 
Experiments were carried out with a minimum of 3 independent 
replicas. Comparisons of the means were performed by analysis of 
variance (ANOVA) with a significance level of 5.0% (α= 0.05) followed 
by Fisher’s least significant difference test. 
 
Conclusions 
In the present study, two novel, stable and smart NLC 
formulations were successfully synthesized by ultrasonication 
technique in the presence of capric triglyceride or olive oil: 
(8HQ-Pt)-NLCA and (8HQ-Pt)-NLCB. 
According to TEM and DLS results that the nanoparticles 
displayed spherical shape and narrow size distribution with low 
PdI (lower than 0.25) which are indicatives of the incorporation 
of 8HQ-Pt compound into the NLCs. Besides, an efficient 
encapsulation higher than 80% were founded for both formulations 
In addition, the physicochemical characterization of the 
formulations by FTIR, TGA, DSC and XRD proved the thermal 
properties, surface composition and crystalline structures of the 
free 8HQ-Pt compound, loaded and empty formulations. 
Compared to the free drug, both nanoparticles showed a slower 
and more sustained release profile during 72 h, which 
guarantee the biodistribution of the nanoparticles as such, at 
the same time that they release their cargo. The cytotoxicity 
effect, cell uptake and apoptosis assays of 8HQ-Pt compound 
loaded nanostructured lipid carrier (NLC) formulations were 
evaluated in a dose-dependent manner on human colon 
adenocarcinoma cell line HT-29. (8HQ-Pt)-NLCA showed similar 
effects with free 8HQ-Pt compound on HT-29 cells but without 
the deleterious effects of the free drug, and with enhanced 
biocide activity over cancer cells. Additionally, the nanosystems 
may provide other advantages over the free drug: protection 
from in vivo degradation, improved biodistribution profile and 
decreased undesirable side effects. Finally, our study suggests 
that 8HQ-Pt compound loaded NLCs could be a promising drug 
delivery system for colorectal cancer treatment with enhanced 
therapeutic efficacy. 
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